Pfizer drug acquired in $11B buyout confirms benefit in colon cancer
The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...
Pfizer Beats Profit Estimates on Heart Disease Drug, COVID Vaccine Sales
(Reuters) -U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by strong sales of ...
BioPharma Dive1d
Pfizer taps former Novartis exec to lead cancer drug push
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections
AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...
FiercePharma6d
Pfizer's Braftovi combo on track for full approval in win for FDA's Project FrontRunner
Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...
Pfizer imposes its drugs in Russia, and the money goes APU — TC Readovka
Despite loud statements about leaving, the American company Pfizer continues to promote its drugs in Russia, using opaque schemes, and transfers part of the income to the Armed Forces of Ukraine.
FierceBiotech5d
Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates
Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
MedCity News6d
Pfizer Drug Hits Goals of Colorectal Cancer Study, Clearing Way to Seek Full FDA Approval
A Pfizer drug recently awarded accelerated FDA approval in colorectal cancer now has additional data showing it met key goals in its pivotal study, results that could support an application ...